Ventas Inc. (0LO4)
London Exchange · UK · prices in USD · close of 21 Oct 2026
Key indicators
| Last close | USD 85.67 |
|---|---|
| 52-week range | 68.95 – 103.67 |
| Return, 1 month / 3 months | −1.6% / −12.5% |
| Return, 1 year / 3 years | +20.7% / +128.1% |
| Trend | Below its 200-day average |
| RSI (14) | 50 |
| Volatility (1 year) | 22.7% |
| Worst drawdown (1 year) | -19.2% |
| Average daily value traded | 0.07M USD |
| Dividend yield | 0.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ventas Inc. is a real estate investment trust that owns and operates healthcare-related properties. Its portfolio includes senior housing communities operated with care partners, medical office buildings leased to physicians and health systems, and research and life science facilities. The company earns rental income and property-level returns from these holdings, serving healthcare providers, senior living operators and medical tenants. Ventas is based in Chicago, Illinois, in the United States.
On this site Ventas Inc. appears as a stock on the London Exchange (UK), code 0LO4, with prices in US dollars (USD). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ventas Inc. (0LO4) trades on the London Exchange in UK. It last closed at USD 85.67 on 21 October 2026.
Its price-based Market X-Ray is 52 out of 100 (a fair price profile), ranking 1,916 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 20.7% and over the last three months it fell 12.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 51 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -0.8% | ||
| From 52-week high | -14.4% | ||
| Momentum | 48 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -12.5% | ||
| 6-month return | 2.1% | ||
| 12-month return, skipping the last month | 22.7% | ||
| Stability (higher is calmer) | 78 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 22.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -19.2% | ||
| Liquidity | 27 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.07M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 41 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.6% | ||
| Years with dividends | 5 |
Strengths
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +1.0% |
|---|---|
| 1 month | −1.6% |
| 3 months | −12.5% |
| 6 months | +2.1% |
| 1 year | +20.7% |
| 3 years | +128.1% |
| 5 years | – |
Signals
| 50-day / 200-day average | 88.21 / 86.38 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.97 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 31 Dec 2025 | USD 0.4800 |
| 29 Sep 2025 | USD 0.4800 |
| 27 Jun 2025 | USD 0.4800 |
| 31 Mar 2025 | USD 0.4800 |
| 31 Dec 2024 | USD 0.4500 |
| 30 Sep 2024 | USD 0.4500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.